CompareSupplements

Retatrutidevssemaglutide

Retatrutide takes off more weight in its trials. Semaglutide is the one you can get, and the one with a proven heart benefit and an FDA approval for a form of fatty liver disease. Both are compared below on the same counting rule, using trial results published to November 2026.

The short answer

Retatrutide produces more weight loss than semaglutide in trials: about 25% of body weight at 80 weeks on 12 mg in TRIUMPH-1, against about 15% on semaglutide 2.4 mg (Wegovy) and about 19% on semaglutide 7.2 mg (Wegovy HD), all counted the same way, including people who stopped the drug. In the one head-to-head trial, in type 2 diabetes, retatrutide 12 mg took off 20.9% vs 9.4% on Ozempic 2 mg, counted as if everyone stayed on treatment (Lilly early results, October 2026). Retatrutide is not approved anywhere as of November 2026 and has no proven heart benefit; semaglutide is FDA approved for weight, heart risk reduction, kidney disease in type 2 diabetes, and MASH (fatty liver with inflammation) with moderate to advanced scarring, short of cirrhosis. Retatrutide leads on size of effect; semaglutide leads on proven outcomes.

Ask AI about this pageChatGPTClaudePerplexity
CompoundRetatrutideEli Lilly's weekly triple-hormone injection has produced some of the largest weight-loss results reported in drug trials. What each trial found, why the headline figures disagree, the side effects, the blood-test changes and where approval stands as of November 2026.CompoundsemaglutideThe weekly GLP-1 drug behind Ozempic and Wegovy: what the trials found, how often the side effects hit, what happens when you stop, and the lab results it moves.

The differences that matter

  1. 01
    More weight lost vs more outcomes proven

    Retatrutide wins on the numbers a scale or an MRI can show: about 25% of body weight and about 86% of liver fat gone in its trials 4 9. Semaglutide wins on what has been proven to happen to people: 20% fewer heart attacks, strokes and cardiovascular deaths in people with existing heart disease in SELECT 11, and fatty liver inflammation resolved on biopsy in about 63% of people in ESSENCE 10. Fat lost on a scale or an MRI is a stand-in measure; fewer heart attacks and healthier liver tissue on biopsy are outcomes, and only semaglutide has shown those.

Retatrutide takes off more weight than semaglutide in trials, but only semaglutide is approved, and only semaglutide has a proven heart benefit and an FDA approval for a form of fatty liver disease. Semaglutide has been prescribed in the US since 2017, as Ozempic for diabetes and Wegovy for weight. Retatrutide, Eli Lilly's triple-receptor drug, has the largest weight-loss figures yet published for a drug of this kind and none of that track record.

Retatrutide takes off more weight; semaglutide has the proof and a prescription

SemaglutideApproved, with a proven heart benefit and biopsy-confirmed liver improvement
Ozempic, Wegovy, Wegovy HD (Novo Nordisk)
Receptors it acts onGLP-1 only
Dose and scheduleWeekly injection, 0.25 mg rising to 2.4 mg or 7.2 mg; a daily pill also exists
FDA status, November 2026Approved for type 2 diabetes, kidney disease in type 2 diabetes (Ozempic), weight, heart risk reduction, and fatty liver with inflammation and scarring short of cirrhosis (MASH with fibrosis)
Weight loss, no diabetes14.9% on 2.4 mg at 68 weeks; 18.7% on 7.2 mg at 72 weeks
Weight loss, type 2 diabetes9.4% on Ozempic 2 mg at 80 weeks (TRANSCEND-T2D-2)
A1C drop, type 2 diabetes1.8 points on Ozempic 2 mg (TRANSCEND-T2D-2)
Heart outcomes20% fewer heart attacks, strokes and cardiovascular deaths in adults with existing heart disease (SELECT)
LiverFatty liver inflammation resolved on biopsy in 63% vs 34% on placebo (ESSENCE); liver-outcome results still pending
Skin tingling (dysesthesia)6.0% on 2.4 mg; 22.9% on 7.2 mg
How people get itPrescription
RetatrutideBigger weight loss; not approved, no outcomes data
Investigational (Eli Lilly)
Receptors it acts onGLP-1, GIP and glucagon
Dose and scheduleWeekly injection, raised step by step to 9 mg or 12 mg in trials
FDA status, November 2026Not approved; Lilly plans to file in early 2027
Weight loss, no diabetes25.0% on 12 mg at 80 weeks (TRIUMPH-1)
Weight loss, type 2 diabetes20.9% on 12 mg at 80 weeks (TRANSCEND-T2D-2)
A1C drop, type 2 diabetes2.2 points on 12 mg (TRANSCEND-T2D-2)
Heart outcomesNo outcomes trial reported; resting heart rate rises
LiverAbout 86% less liver fat on MRI at 48 weeks; no biopsy trial reported
Skin tingling (dysesthesia)12.5% on 12 mg (TRIUMPH-1); 20.9% on 12 mg (TRIUMPH-4)
How people get itClinical trials only
Weight figures for people without diabetes count everyone randomized, including people who stopped the drug (the treatment-regimen basis). The TRANSCEND-T2D-2 figures are on the efficacy basis, as if everyone stayed on treatment. Sources: STEP 1 2, STEP UP 3, TRIUMPH-1 4, TRIUMPH-4 5, TRANSCEND-T2D-2 7, ESSENCE 10, SELECT 11, Wegovy label 13, FLOW 16.

One receptor vs three: how each drug works

Semaglutide copies GLP-1, a gut hormone released after a meal that slows the stomach, turns down appetite and helps the pancreas release insulin when blood sugar is high. Retatrutide is a single peptide, one molecule rather than a mix, that switches on three receptors: GLP-1, GIP (a second gut hormone, also targeted by tirzepatide, sold as Mounjaro and Zepbound) and glucagon 1.

The glucagon arm is the trade-off. Glucagon raises the energy the body burns and pushes the liver to burn its stored fat, the likely reason retatrutide clears liver fat so quickly. It also nudges blood sugar and heart rate up; in the trials the GLP-1 and GIP effects more than cancel the glucose push, but the heart-rate rise still shows up.

SemaglutideTirzepatideRetatrutide
GLP-1 receptorYesYesYes
GIP receptorNoYesYes
Glucagon receptorNoNoYes
Brand namesOzempic, Wegovy, RybelsusMounjaro, ZepboundNone yet
FormWeekly injection or daily pillWeekly injectionWeekly injection (in trials)

How much weight do people lose on each?

Roughly 15% on standard Wegovy, 19% on the high dose and 25% on retatrutide 12 mg, counted the same way. In STEP 1, 1,961 adults with obesity or overweight and no diabetes took semaglutide 2.4 mg weekly for 68 weeks and lost 14.9% of body weight, against 2.4% on placebo 2. In STEP UP, the 7.2 mg dose took off 18.7% at 72 weeks, against 15.6% on 2.4 mg and 3.9% on placebo 3; the FDA approved that dose as Wegovy HD in March 2026 13.

Retatrutide 12 mg took off 24.2% at 48 weeks in its Phase 2 trial 1, and 25.0% at 80 weeks in TRIUMPH-1, a Phase 3 trial of 2,339 adults without diabetes, against 3.9% on placebo 4.

Why one article says 25% and another says 28%

The treatment-regimen figure counts everyone who was randomized, including people who stopped the drug or skipped doses. The efficacy figure estimates what would have happened if everyone had stayed on treatment as planned, so it comes out higher. For retatrutide 12 mg in TRIUMPH-1, that is 25.0% on the first basis and 28.3% on the second 4. For semaglutide 2.4 mg in STEP 1, it is 14.9% and 16.9% 2.

So when an article puts retatrutide's 28.3% beside semaglutide's 14.9%, it is setting a best-case number against an everyone-counted one, and the gap looks bigger than it is. The 28.7% headline from TRIUMPH-4 came from adults with knee osteoarthritis over 68 weeks 5, a different group from TRIUMPH-1. People with type 2 diabetes also lose less on every drug in this class: in TRIUMPH-2, retatrutide 12 mg took off 18.8% on the treatment-regimen basis 6.

TrialDrug and doseWeeksWho took partEveryone randomized (treatment-regimen)If all stayed on treatment (efficacy)Placebo
STEP 1 2Semaglutide 2.4 mg68Obesity or overweight, no diabetes14.9%16.9%2.4%
STEP UP 3Semaglutide 7.2 mg72Obesity, no diabetes18.7%20.7%3.9%
SURMOUNT-5 8Tirzepatide 15 mg vs semaglutide 2.4 mg72Obesity, no diabetes20.2% vs 13.7%Not listedNo placebo arm
TRIUMPH-1 4Retatrutide 12 mg80Obesity or overweight, no diabetes25.0%28.3%3.9%
TRIUMPH-4 5Retatrutide 12 mg68Obesity and knee osteoarthritisNot yet published28.7% (company early results)2.1%
TRIUMPH-2 6Retatrutide 12 mg80Obesity or overweight with type 2 diabetes18.8%20.8%5.1% (treatment-regimen); 4.0% (efficacy)
TRANSCEND-T2D-2 7Retatrutide 12 mg vs Ozempic 2 mg80Type 2 diabetes on metformin, with or without an SGLT2 inhibitorNot yet published20.9% vs 9.4%No placebo arm
Weight lost at the end of each trial, everyone counted
% of body weight lostSemaglutide 2.4 mg (68 wk)Semaglutide 7.2 mg (72 wk)Tirzepatide 15 mg (72 wk)Retatrutide 12 mg (80 wk)
Published end points on the treatment-regimen basis, which counts everyone randomized: STEP 1 2, STEP UP 3, SURMOUNT-5 8 and TRIUMPH-1 4, all in people without diabetes. These are separate trials of different lengths, not one head-to-head.

Has anyone tested them head to head?

One trial has compared them directly, in people with type 2 diabetes. In TRANSCEND-T2D-2, 1,298 adults whose diabetes was not controlled on metformin, with or without an SGLT2 inhibitor, were randomized to retatrutide 9 mg, retatrutide 12 mg or Ozempic 2 mg for 80 weeks. A1C fell 2.2 points on both retatrutide doses and 1.8 points on Ozempic; body weight fell 19.5% and 20.9% on retatrutide and 9.4% on Ozempic. Retatrutide also lowered non-HDL cholesterol (all the cholesterol except HDL), triglycerides and systolic blood pressure more than Ozempic did 7.

That result has four limits. Lilly announced it as topline data (the company's early headline results) in October 2026, before journal publication. The trial was open-label, so everyone knew which drug they were on. The figures are on the efficacy basis, as if everyone stayed on treatment. And Ozempic 2 mg is the top diabetes dose, below Wegovy's 2.4 mg and 7.2 mg weight doses. No trial has yet pitted retatrutide against Wegovy in people without diabetes. The closest proxy is SURMOUNT-5, where tirzepatide took off 20.2% against 13.7% for semaglutide at 72 weeks 8; Lilly is now testing retatrutide against tirzepatide in TRIUMPH-5 7.

Blood sugar and type 2 diabetes

Both drugs lower A1C, the three-month average of blood sugar, by large amounts. Semaglutide's record runs from Ozempic's approval in 2017. Retatrutide 12 mg lowered A1C by 1.5 points against 0.2 on placebo over 80 weeks in TRIUMPH-2, on the efficacy basis 6. As our comparison of the two sugar tests puts it, "A1C asks how high your sugar has run on average, after-meal peaks included" (A1C vs fasting glucose). You can turn an A1C into an average glucose with the A1C calculator, and the type 2 diabetes guide covers the cutoffs.

Neither drug often causes low blood sugar on its own, because the insulin release they trigger depends on glucose being high. The risk rises when either is added to insulin or a sulfonylurea such as glipizide or glimepiride.

Fatty liver on MRI vs fatty liver on biopsy

Retatrutide has the largest liver-fat reductions reported for a drug in this class. In a Phase 2 MRI substudy of 98 people with at least 10% liver fat, 12 mg cut liver fat by about 86% at 48 weeks, and 93% of people ended below 5%, the line for a normal liver 9. Semaglutide's liver evidence is a different kind of proof. In ESSENCE, a biopsy trial in people with MASH (fatty liver with inflammation and cell injury), semaglutide 2.4 mg resolved the inflammation without worsening scarring in 62.9% of people against 34.3% on placebo at 72 weeks 10. The FDA gave Wegovy accelerated approval in August 2025 for MASH with moderate to advanced fibrosis, in people without cirrhosis, based on those biopsy results; the trial's liver-outcome results are still to report 13.

An MRI measures how much fat sits in the liver. A biopsy shows inflammation, cell injury and scarring, and scarring is what predicts liver failure. A drug can empty liver fat fast and still need to show that it reverses scarring; retatrutide has not reported a biopsy trial. On a blood test, ALT usually drifts down as liver fat clears. To find out whether there is scarring, ask your clinician for a FIB-4 score (worked out from AST, ALT, platelets and age) and, if it is not low, a FibroScan. The fatty liver guide and liver enzymes, explained cover how to read ALT and AST, and the AST/ALT ratio calculator works out the ratio from your report.

What is known about the heart

In SELECT, 17,604 adults with established heart disease and overweight or obesity, without diabetes, took semaglutide 2.4 mg or placebo and were followed for an average of about 40 months. Heart attacks, strokes and cardiovascular deaths happened to 6.5% on semaglutide and 8.0% on placebo, 20% fewer 11, and that trial is the basis for Wegovy's heart risk indication.

Retatrutide has no completed heart-outcomes trial. TRIUMPH-3, in 1,949 people with severe obesity and established heart disease, reported 22.6% weight loss on 12 mg at 80 weeks against 3.2% on placebo. There were 27 heart attacks, strokes or cardiovascular deaths on retatrutide and 23 on placebo (hazard ratio 1.12, 95% CI 0.64 to 1.96), too few events to show benefit or harm either way 12. Retatrutide also raises resting heart rate, and the Phase 2 report described the pattern in one line.

Dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.Jastreboff and colleagues, retatrutide Phase 2 trial, New England Journal of Medicine, 2023 1

Side effects compared

Nausea, diarrhea, vomiting and constipation are the most common side effects of both drugs, clustering in the weeks after each dose increase.

Side effectSemaglutideRetatrutideTrial
Skin tingling or burning (dysesthesia), no diabetes6.0% on 2.4 mg; 22.9% on 7.2 mg (placebo 0.5%)12.5% on 12 mg (placebo 0.9%) in TRIUMPH-1; 8.8% on 9 mg and 20.9% on 12 mg (placebo 0.7%) in TRIUMPH-4STEP UP 3; TRIUMPH-1 4; TRIUMPH-4 5
Dysesthesia with type 2 diabetesNot measured in the same trial7% on 12 mg (placebo 1%)TRIUMPH-2 6
Nausea, type 2 diabetes21.3% on Ozempic 2 mg23.8% on 12 mgTRANSCEND-T2D-2 7
Diarrhea, type 2 diabetes26.4% on Ozempic 2 mg32.7% on 12 mgTRANSCEND-T2D-2 7
Stopped for side effects, type 2 diabetes2.7% on Ozempic 2 mg7.9% on 12 mgTRANSCEND-T2D-2 7
Stopped for side effects, no diabetes7.0% on 2.4 mg (placebo 3.1%)11.3% on 12 mg (placebo 4.9%)STEP 1 2; TRIUMPH-1 4
Resting heart rateSmall rise (about 1 to 4 beats per minute on average)Dose-dependent rise, peaking around week 24 and easing afterWegovy label 13; Phase 2 1

Semaglutide causes dysesthesia too. STEP UP found it in 22.9% of people on semaglutide 7.2 mg 3, about the same as the 20.9% on retatrutide 12 mg in TRIUMPH-4, which suggests it tracks high drug exposure or fast weight loss rather than retatrutide's glucagon arm alone. Tingling hands and feet covers the other causes worth ruling out. Lilly reported the TRIUMPH-4 cases as "generally mild" and said they "rarely led to treatment discontinuation" 5.

Semaglutide's label lists the serious risks of this class: pancreatitis, gallbladder disease, kidney injury from dehydration, worsening diabetic eye disease when blood sugar falls quickly, and food in the lungs under anesthesia. It also carries a boxed warning for a rare thyroid cancer (medullary thyroid carcinoma, MTC) seen in preclinical studies, and it is not used by anyone with a personal or family history of MTC or MEN2, an inherited condition that causes gland tumors 13. Retatrutide has no label yet; its trials track the same risks.

What changes on your blood test

Several markers move in predictable directions on both drugs, and the useful comparison is against your own results from before you started. Before a first dose, a baseline A1C, lipid panel, ALT and AST, creatinine and eGFR (the kidney filtering rate) are worth asking your clinician about, with a repeat at about 12 weeks; why a trend beats a single reading explains the logic.

MarkerUsual directionOrdinary on treatmentCall your doctor if
A1C and fasting glucoseFallA1C down 1 to 2 points in type 2 diabetes; a small fall without diabetesGlucose under 70 mg/dL or symptoms of a low, mainly with insulin or a sulfonylurea
TriglyceridesFallOften a large drop as weight comes offThey rise instead, or reach 500 mg/dL or more
ALTFalls as liver fat clearsDrifts toward the normal range over monthsAbove 3 times the upper limit, or with yellow skin or dark urine
Lipase and amylaseCan riseA mild rise with no symptoms is common and on its own usually does not mean pancreatitis 14Severe upper belly pain, with or without vomiting, needs same-day care whatever the lipase result
Creatinine and eGFR (kidney filtering rate)SteadySmall shifts within your usual rangeCreatinine climbs or eGFR drops after vomiting or diarrhea
Resting heart rateUp a few beats1 to 4 beats per minute higher on semaglutide; a rise that eases over months on retatrutideStays above 100, or with palpitations, chest pain or fainting
Thyroid testsNo routine testTSH does not track the C-cell warningA neck lump, hoarseness or trouble swallowing

Amylase behaves like lipase on these drugs. TSH tracks thyroid output, not the C-cells behind the boxed warning, and the label does not ask for routine thyroid screening.

Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with WEGOVY.Wegovy (semaglutide) US prescribing information, Novo Nordisk 13

Free, no accountRead your blood testHave a panel from before you started and one from around three months in? Read every line of both against your own baseline.Read my results

Keeping muscle while the weight comes off

On any drug in this class, part of the weight lost is lean mass. In STEP 1's DEXA substudy, lean mass fell along with fat, though fat fell faster, so the share of the body that was lean went up 2. At 25% weight loss the absolute amount of muscle at stake is larger than at 15%, which makes protein intake and resistance training matter more on retatrutide-sized losses. A scale cannot tell fat from muscle; a DEXA scan (a low-dose X-ray body composition scan) can. As our DEXA guide puts it, "lean mass on a DEXA moves with water", so "read lean mass trends across months" (DEXA results explained). The lean body mass calculator gives a rough estimate between scans, and visceral fat covers the deep belly fat the same scan reports.

CalculatorProtein calculatorWorks out a daily protein target from your weight, a starting point for keeping muscle during fast weight loss. If you have kidney disease, check any protein target with your doctor first.Work it out

Can you get retatrutide now?

Retatrutide is not approved anywhere as of November 2026 and is available only inside clinical trials. Lilly said in July 2026 that it plans to file with the FDA in the first quarter of 2027 12.

Semaglutide is prescribed as Ozempic for type 2 diabetes and as Wegovy for weight: a weekly injection at 2.4 mg or the 7.2 mg HD dose, or a daily Wegovy pill approved in December 2025. Wegovy is approved for adults with a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure, type 2 diabetes or high cholesterol 13. The BMI calculator shows where you sit against those lines; whether a prescription fits is a decision for you and your prescriber. Insurance usually covers Ozempic for diabetes; coverage of weight doses varies by plan, and Novo Nordisk also sells Wegovy at a self-pay price. Weight loss gathers the related guides.

Thinking of switching from semaglutide?

Today the approved options a prescriber may weigh beyond Wegovy 2.4 mg are Wegovy HD 7.2 mg or a change to tirzepatide. No study has published results on moving people from semaglutide to retatrutide. Milligrams do not convert between these drugs: each peptide has its own strength at its receptors and its own dose-increase schedule, so 12 mg of retatrutide is not five times as strong as 2.4 mg of semaglutide, and no equivalent dose exists.

How the options line up: semaglutide suits someone who wants an approved drug now, with proven heart, kidney or MASH benefit. Tirzepatide is the approved route to more weight loss. A retatrutide trial suits someone after the most weight or liver fat lost who can accept trial conditions, an unproven heart record and the heart-rate rise. Which fits you is a conversation with your prescriber.

Questions worth taking to your prescriber:

  • Is my current dose the most semaglutide can do for me, or is there room, including the 7.2 mg dose?
  • Would tirzepatide, which beat semaglutide in SURMOUNT-5, suit my health history?
  • Am I eligible for a retatrutide trial listed on ClinicalTrials.gov?
  • Which blood tests should we repeat after a change, and when?
Free, no accountDrop in your lab report and see every marker explained in plain words, placed on the body, against your lab's range. It's read on your device: nothing is uploaded and nothing is kept.

Questions

Is retatrutide stronger than Ozempic?

For weight, it did better in the one head-to-head trial so far. In TRANSCEND-T2D-2, adults with type 2 diabetes lost 20.9% of body weight on retatrutide 12 mg against 9.4% on Ozempic 2 mg over 80 weeks, and A1C fell 2.2 points against 1.8 7. Those are early, open-label company results, and Ozempic 2 mg is below the Wegovy weight doses.

Is retatrutide better than Wegovy 7.2 mg?

For weight, the numbers favor retatrutide, but no trial has compared them. Counting everyone randomized, retatrutide 12 mg took off 25.0% at 80 weeks in TRIUMPH-1 4 and semaglutide 7.2 mg took off 18.7% at 72 weeks in STEP UP 3, in separate trials. Wegovy HD is approved, with semaglutide's heart outcomes data behind it; retatrutide has neither.

When will retatrutide be approved?

Not yet, and not in 2026. Lilly plans to submit retatrutide to the FDA in the first quarter of 2027 12, and approval timing then depends on the FDA review. It is available only in clinical trials.

What dose of retatrutide equals my semaglutide dose?

There is no equivalent dose. Retatrutide and semaglutide are different molecules acting on different receptors, with different strengths and dose-increase schedules, so milligrams do not translate between them. Any dose decision belongs with a prescriber, and retatrutide is only given inside trials.

What is the tingling side effect?

It is dysesthesia: tingling, burning or unusual sensitivity of the skin. It was reported in 12.5% of people on retatrutide 12 mg in TRIUMPH-1 4 and 20.9% in TRIUMPH-4 5, and in 22.9% on semaglutide 7.2 mg in STEP UP 3, mostly mild. Tell your prescriber if it starts, and get numbness, weakness or spreading tingling checked.

Will retatrutide work if semaglutide stopped working?

No study has tested it. Retatrutide adds GIP and glucagon activity on top of GLP-1, so it works through more routes, but whether that helps someone whose weight has stalled on semaglutide is unknown. The approved options today are semaglutide 7.2 mg or tirzepatide, and retatrutide is available only in trials.

Retatrutide vs tirzepatide: which takes off more weight?

No published trial has compared them yet; Lilly is running TRIUMPH-5 to find out 7. Across separate trials, retatrutide 12 mg took off about 25% of body weight at 80 weeks counting everyone randomized 4, while tirzepatide took off 20.2% at 72 weeks in SURMOUNT-5 8.

Does retatrutide help fatty liver more than semaglutide?

It removes liver fat faster: about 86% less liver fat on MRI at 48 weeks on 12 mg 9. Semaglutide has the stronger proof, because a biopsy trial showed it resolved liver inflammation in 62.9% of people against 34.3% on placebo 10, and it has accelerated FDA approval for MASH with moderate to advanced fibrosis, short of cirrhosis 13. Retatrutide has no biopsy results yet.

Citations
  1. Jastreboff AM, Kaplan LM, Frias JP et al. Triple-hormone-receptor agonist retatrutide for obesity: a phase 2 trial. N Engl J Med 2023;389:514-526.
  2. Wilding JPH, Batterham RL, Calanna S et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med 2021;384:989-1002.
  3. Wharton S et al. Once-weekly semaglutide 7.2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial. Lancet Diabetes Endocrinol 2025;13:949-963.
  4. Jastreboff AM et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity (TRIUMPH-1). N Engl J Med 2026;395:1781-1793.
  5. Eli Lilly and Company. Lilly's triple agonist retatrutide delivered weight loss of up to an average of 71.2 lbs (TRIUMPH-4 topline results). Press release, 11 December 2025.
  6. Bellido V, le Roux CW, Ekinci EI et al. Retatrutide in adults with obesity and type 2 diabetes (TRIUMPH-2): a double-blind, parallel-group, randomised, placebo-controlled, phase 3 trial. Lancet 2026.
  7. HCPLive. TRANSCEND-T2D-2: retatrutide beats semaglutide 2 mg on A1C and weight loss (Eli Lilly topline results, 28 October 2026).
  8. Aronne LJ, Horn DB, le Roux CW et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med 2025;393:26-36.
  9. Sanyal AJ, Kaplan LM, Frias JP et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med 2024;30:2037-2048.
  10. Sanyal AJ, Newsome PN, Kliers I et al. Phase 3 trial of semaglutide in metabolic dysfunction-associated steatohepatitis (ESSENCE). N Engl J Med 2025;392:2089-2099.
  11. Lincoff AM, Brown-Frandsen K, Colhoun HM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). N Engl J Med 2023;389:2221-2232.
  12. HCPLive. Retatrutide meets phase 3 weight loss endpoints in 2 obesity trials (TRIUMPH-2 and TRIUMPH-3 topline results, cardiovascular events, and FDA submission planned for Q1 2027). 23 July 2026.
  13. Novo Nordisk. Wegovy (semaglutide) injection, US prescribing information.
  14. Steinberg WM, Buse JB, Ghorbani MLM et al. Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial. Diabetes Care 2017;40:966-972.
  15. US Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss.
  16. Perkovic V, Tuttle KR, Rossing P et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes (FLOW). N Engl J Med 2024;391:109-121.

Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.